Answer:
i wish there was an answer here i needed it
<span>A drug used to treat CML, imatinib, binds to the active site of Abl kinase. Why does this drug work to treat this type of cancer?
</span><span>B) By binding to the active site, the drug prevents the ability of Abl kinase to bind to its substrate.
</span>
Imatinib works against CML by binding close to the ATP binding site of bcr-abl. The binding results to the<span> locking in of the bcr-abl to a closed or self-inhibited conformation and inhibiting the enzyme activity of the protein </span><span>semi-competitively.</span>
